CNS

Compass Pathways, now leading the race toward regulatory approval for a classic psychedelic, mapped out its strategy behind what could become one of the industry’s more unconventional drug launches.

Headlamp Health's Lumos AI uses a ‘neurosymbolic’ multi-agent framework to improve CNS trial patient selection, targeting the heterogeneity that drives neuroscience's high attrition rate.

Praxis Precision Medicines is planning to shift from a clinical-stage company to a competitive commercial player in CNS, with the potential to launch multiple blockbuster medicines in the near future.

European CNS specialist rolls out a value-added methylphenidate and a first-to-market guanfacine generic as it sharpens its European ADHD strategy.

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

Controlling for personality traits in clinical studies can deliver significant improvements in trial precision, with implications particularly relevant for CNS drug development

FDA approval of a new indication for Teva’s risperidone long-acting injectable Uzedy expands its reach beyond schizophrenia, unlocking a major growth opportunity in the bipolar I disorder market.

2026 is positioned as a breakout year for the psychedelic therapeutics sector, with multiple players expected to deliver defining Phase III results – creating momentum across the industry.

MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.

Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.

A massive new proteomics dataset promises to accelerate target identification, biomarker discovery and precision medicine approaches in Alzheimer's, Parkinson's and other neurodegenerative diseases.